These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 17062331)

  • 21. Safety and tolerability of solifenacin add-on therapy to α-blocker treated men with residual urgency and frequency.
    Kaplan SA; McCammon K; Fincher R; Fakhoury A; He W
    J Urol; 2013 Jan; 189(1 Suppl):S129-34. PubMed ID: 23234618
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Solifenacin succinate for the treatment of symptoms of overactive bladder.
    Maniscalco M; Singh-Franco D; Wolowich WR; Torres-Colón R
    Clin Ther; 2006 Sep; 28(9):1247-72. PubMed ID: 17062299
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tolerability of solifenacin and oxybutynin immediate release in older (> 65 years) and younger (≤ 65 years) patients with overactive bladder: sub-analysis from a Canadian, randomized, double-blind study.
    Herschorn S; Pommerville P; Stothers L; Egerdie B; Gajewski J; Carlson K; Radomski S; Drutz H; Schulz J; Barkin J; Hirshberg E; Corcos J
    Curr Med Res Opin; 2011 Feb; 27(2):375-82. PubMed ID: 21175373
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Solifenacin as add-on therapy for overactive bladder symptoms in men treated for lower urinary tract symptoms--ASSIST, randomized controlled study.
    Yamaguchi O; Kakizaki H; Homma Y; Takeda M; Nishizawa O; Gotoh M; Yokoyama O; Seki N; Yoshida M;
    Urology; 2011 Jul; 78(1):126-33. PubMed ID: 21601248
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment outcomes in the STAR study: a subanalysis of solifenacin 5 mg and tolterodine ER 4 mg.
    Chapple CR; Fianu-Jonsson A; Indig M; Khullar V; Rosa J; Scarpa RM; Mistry A; Wright DM; Bolodeoku J;
    Eur Urol; 2007 Oct; 52(4):1195-203. PubMed ID: 17574730
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial.
    Cardozo L; Hessdörfer E; Milani R; Arañó P; Dewilde L; Slack M; Drogendijk T; Wright M; Bolodeoku J;
    BJU Int; 2008 Nov; 102(9):1120-7. PubMed ID: 18990175
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Solifenacin significantly improves all symptoms of overactive bladder syndrome.
    Chapple CR; Cardozo L; Steers WD; Govier FE
    Int J Clin Pract; 2006 Aug; 60(8):959-66. PubMed ID: 16893438
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of solifenacin to treat overactive bladder symptoms in patients with idiopathic normal pressure hydrocephalus: an open-label, multicenter, prospective study.
    Chung JH; Lee JY; Kang DH; Ha US; Lee SH; Ham WS; Cho KS; Han JH; Park J; Yoo TK; Lee SW
    Neurourol Urodyn; 2012 Sep; 31(7):1175-80. PubMed ID: 22674356
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Overactive bladder. When it's pressing, immediate help is indicated].
    Widhalm S
    MMW Fortschr Med; 2008 May; 150(20):44-5. PubMed ID: 18605642
    [No Abstract]   [Full Text] [Related]  

  • 30. Solifenacin for overactive bladder: patient-reported outcomes from a large placebo-controlled trial.
    Toglia MR; Serels SR; Laramée C; Karram MM; Nandy IM; Andoh M; Seifeldin R; Forero-Schwanhaeuser S
    Postgrad Med; 2009 Sep; 121(5):151-8. PubMed ID: 19820284
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adding to the evidence base: efficacy of solifenacin for overactive bladder symptoms, symptom bother, and health-related quality of life in patients by duration of self-reported symptoms: a secondary analysis of the VIBRANT study.
    Sublett CM
    Urol Nurs; 2012; 32(1):47-9. PubMed ID: 22474865
    [No Abstract]   [Full Text] [Related]  

  • 32. Prospective open label study of solifenacin for overactive bladder in children.
    Bolduc S; Moore K; Nadeau G; Lebel S; Lamontagne P; Hamel M
    J Urol; 2010 Oct; 184(4 Suppl):1668-73. PubMed ID: 20728124
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of solifenacin on overactive bladder symptoms, symptom bother and other patient-reported outcomes: results from VIBRANT - a double-blind, placebo-controlled trial.
    Vardy MD; Mitcheson HD; Samuels TA; Wegenke JD; Forero-Schwanhaeuser S; Marshall TS; He W
    Int J Clin Pract; 2009 Dec; 63(12):1702-14. PubMed ID: 19930331
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of solifenacin for overactive bladder symptoms, symptom bother, and health-related quality of life in patients by duration of self-reported symptoms: a secondary analysis of the VIBRANT study.
    Gollar KM; Young DG; Bailen J; He W; Forero-Schwanhaeuser S
    Urol Nurs; 2012; 32(1):38-46, 50. PubMed ID: 22474864
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction: ameliorative effect of solifenacin succinate (Vesicare), a bladder-selective antimuscarinic agent, on overactive bladder symptoms, especially urgency episodes.
    Ohtake A; Sato S; Sasamata M; Miyata K
    J Pharmacol Sci; 2010; 112(2):135-41. PubMed ID: 20134114
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment with solifenacin increases warning time and improves symptoms of overactive bladder: results from VENUS, a randomized, double-blind, placebo-controlled trial.
    Karram MM; Toglia MR; Serels SR; Andoh M; Fakhoury A; Forero-Schwanhaeuser S
    Urology; 2009 Jan; 73(1):14-8. PubMed ID: 18995887
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Urodynamic parameters after solifenacin treatment in men with overactive bladder symptoms and detrusor underactivity.
    Ronchi P; Gravina GL; Galatioto GP; Costa AM; Martella O; Vicentini C
    Neurourol Urodyn; 2009; 28(1):52-7. PubMed ID: 18671288
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of solifenacin on quality of life, medical care use, work productivity, and health utility in the elderly: an exploratory subgroup analysis.
    Zinner N; Noe L; Rasouliyan L; Marshall T; Runken MC; Seifeldin R
    Am J Geriatr Pharmacother; 2009 Dec; 7(6):373-82. PubMed ID: 20129258
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Factors associated with a better therapeutic effect of solifenacin in patients with overactive bladder syndrome.
    Hsiao SM; Lin HH; Kuo HC
    Neurourol Urodyn; 2014 Mar; 33(3):331-4. PubMed ID: 23494586
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomised, multicentre, placebo-controlled, double-blind crossover study investigating the effect of solifenacin and oxybutynin in elderly people with mild cognitive impairment: the SENIOR study.
    Wagg A; Dale M; Tretter R; Stow B; Compion G
    Eur Urol; 2013 Jul; 64(1):74-81. PubMed ID: 23332882
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.